Gregg Lapointe

Gregg Anthony Lapointe is the founder of Cerium Pharmaceuticals, Inc. Current positions include Chairman at Rigel Pharmaceuticals, Inc. since 2022, Independent Director at Soligenix, Inc. since 2009, Director at S1 BioPharma, Inc. since 2014, Director at Cytori Therapeutics, Inc., and Member-Corporate Council at Child Neurology Foundation.
Former roles include Chief Executive Officer at Essetifin SpA in 2012, Chief Executive Officer at Leadiant Biosciences, Inc. from 2008 to 2012, Independent Director at SciClone Pharmaceuticals LLC from 2011 to 2016, Director at Questcor Pharmaceuticals, Inc. from 2005 to 2007, Independent Director at ImmunoCellular Therapeutics Ltd. from 2015 to 2017, Independent Director at Astria Therapeutics, Inc. from 2019 to 2026, Independent Director at Plus Therapeutics, Inc. from 2017 to 2020, Director at Raptor Pharmaceuticals Corp.
from 2014 to 2016, Director at Pharmaceutical Research & Manufacturers of America from 2009 to 2012, Director at Ajinomoto Cambrooke, Inc., Director at The Signature Group, Inc. (Virginia), Independent Director at Horizon Pharmaceutical LLC in 2015, Member-Corporate Council at Kidney Care Partners, Vice President-Operations & Controller at AstenJohnson, Inc. from 1996 to 2001, Trustee at Keck Graduate Institute of Applied Life Sciences, and Member-Corporate Council at The National Organization for Rare Disorders, Inc. Education includes an MBA from Duke University and undergraduate studies at Concordia University.